Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

N158

Sigma-Aldrich

Naftopidil hydrochloride hydrate

solid

Sinonimo/i:

4-(2-Methoxyphenyl)-α-[(1-naphthalenyloxy)methyl]-1-piperazineethanol hydrochloride hydrate, KT-611

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C24H28N2O3 · xHCl · yH2O
Numero CAS:
Peso molecolare:
392.49 (anhydrous free base basis)
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Stato

solid

Colore

white

Solubilità

methanol: >10 mg/mL
H2O: insoluble

Stringa SMILE

O.Cl.COc1ccccc1N2CCN(CC2)CC(O)COc3cccc4ccccc34

InChI

1S/C24H28N2O3.ClH.H2O/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23;;/h2-12,20,27H,13-18H2,1H3;1H;1H2
INIDYCYXDNFBSV-UHFFFAOYSA-N

Informazioni sul gene

Categorie correlate

Azioni biochim/fisiol

α1-Adrenoceptor antagonist; antihypertensive.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Teruhiko Yokoyama et al.
International journal of urology : official journal of the Japanese Urological Association, 18(3), 225-230 (2011-01-29)
The aim of the present study was to explore the effects of three different types of alpha-1 adrenoceptor blockers (α1-blocker) on lower urinary tract symptoms (LUTS), erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in patients with benign prostatic hyperplasia. A
Eriko Masachika et al.
Anticancer research, 33(3), 887-894 (2013-03-14)
Naftopidil, an α1-adrenoceptor blocker, has been clinically used for the treatment of benign prostate hyperplasia and hypertension. Emerging evidence has shown that naftopidil exhibits an antitumor effect on a variety of cancer types including prostate cancer. The aim of the
Hideki Sakai et al.
Hinyokika kiyo. Acta urologica Japonica, 57(1), 7-13 (2011-02-10)
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50
Yasuo Tsuzaka et al.
International journal of urology : official journal of the Japanese Urological Association, 18(11), 792-795 (2011-09-16)
The aim of the present study was to compare the efficacy of the selective α(1D) -adrenoceptor antagonist naftopidil and the selective α(1A) -adrenoceptor antagonist silodosin (as an example) in the management of ureteral stones in Japanese male patients. A total
Hideyasu Tsumura et al.
International journal of radiation oncology, biology, physics, 81(4), e385-e392 (2011-06-15)
To compare the efficacy of three α(1A)/α(1D)-adrenoceptor (AR) antagonists--naftopidil, tamsulosin, and silodosin--that have differing affinities for the α(1)-AR subtypes in treating urinary morbidities in Japanese men with (125)I prostate implantation (PI) for prostate cancer. This single-institution prospective randomized controlled trial

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.